Arcellx, Inc.
ACLX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for ACLX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ACLX
Arcellx, Inc. is a clinical-stage biotechnology company developing novel cell therapies for cancer, primarily its lead candidate anito-cel (a BCMA-targeted CAR-T therapy) in collaboration with Kite, a Gilead company. The company has incurred significant losses since inception and expects to require substantial additional funding to advance its pipeline and platforms.
Key risk: Substantial capital requirements
BioSniper Score
Based on 4 of 6 signals
Financial data as of Dec 31, 2025.
Tracking 1 pipeline candidate · 2 clinical trials for Arcellx, Inc..
Arcellx, Inc. is a clinical-stage biotechnology company developing novel cell therapies for cancer, primarily its lead candidate anito-cel (a BCMA-targeted CAR-T therapy) in collaboration with Kite, a Gilead company. The company has incurred significant losses since inception and expects to require substantial additional funding to advance its pipeline and platforms.
- Lead product candidate anito-cel is a BCMA-targeted CAR-T cell therapy being developed in collaboration with Kite for the treatment of multiple myeloma [sec_mda · as of 2025-11-05].
- Net losses were $228.9 million for the year ended December 31, 2025, and accumulated deficit was $725.8 million as of that date [sec_mda · as of 2026-02-26].
- Cash and equivalents were $82.9 million as of December 31, 2025 [sec].
- The company is advancing its proprietary D-Domain, ddCAR, and ARC-SparX platforms to expand its pipeline of product candidates [sec_mda · as of 2026-02-26].
- A Phase 1 master protocol study (NCT05457010) for cell therapies in relapsed/refractory multiple myeloma is active but not recruiting [catalyst].
What works
- Arcellx has a strategic collaboration with Kite, a Gilead company, to co-develop and commercialize anito-cel, providing resources and expertise for clinical advancement and potential commercialization [sec_mda · as of 2025-11-05].
- The company's proprietary platforms (D-Domain, ddCAR, ARC-SparX) may enable the development of multiple product candidates beyond anito-cel, offering pipeline diversification [sec_mda · as of 2026-02-26].
- Shareholders' equity was $454.8 million as of December 31, 2025, indicating a strong equity base relative to current cash position [sec].
What to weigh
- Arcellx has incurred net losses every period since its inception in December 2014, with a net loss of $228.9 million in 2025 and an accumulated deficit of $725.8 million as of December 31, 2025 [sec_mda · as of 2026-02-26].
- The company expects operating expenses and capital requirements to increase substantially as it advances anito-cel through clinical trials, regulatory approval, and potential commercialization, requiring significant additional funding [sec_mda · as of 2025-11-05].
- Investment in biopharmaceutical product development is highly risky, with substantial upfront capital expenditures and significant risk that any product candidate may fail to demonstrate adequate efficacy or safety, gain regulatory approval, or become commercially viable [sec_mda · as of 2026-02-26].
From the filings
Quoted directly from source documents.
Arcellx has incurred net losses since inception and expects losses to increase.
“We have incurred losses in each period since our inception in December 2014. Our net losses were $228.9 million and $107.3 million for the years ended December 31, 2025 and 2024, respectively. As of December 31, 2025, we had an accumulated deficit of $725.8 million.”
SEC MD&A · February 26, 2026
The company is advancing anito-cel in collaboration with Kite.
“Advance the clinical program for anito-cel and subsequent clinical trials focused on earlier lines of therapy in collaboration with our partner Kite”
SEC MD&A · November 5, 2025
Arcellx expects to need substantial additional funding.
“we will need substantial additional funds to expand our clinical, regulatory, quality and manufacturing capabilities, whether internally or with third-party partners and collaborators, and advance our product candidates through preclinical studies and clinical trials in order to obtain marketing approval”
SEC MD&A · February 26, 2026
A Phase 1 study for cell therapies in relapsed/refractory multiple myeloma is active but not recruiting.
“Phase 1 Start: Master Protocol for the Phase 1 Study of Cell Therapies for the Treatment of Patients With Relapsed - NCT: NCT05457010. Status: Active, not recruiting.”
Catalysts · November 28, 2022
Catalyst timeline
- 2022-11-28 · Phase 1 Start: Master Protocol for the Phase 1 Study of Cell Therapies for the Treatment of Patients With Relapsed - NCT: NCT05457010. Status: Active, not recruiting. — This Phase 1 study is evaluating cell therapies, including anito-cel, in relapsed/refractory multiple myeloma; the study is active but not recruiting, and data readouts may be forthcoming.
Risks & what to watch (3)›
Key risks
- Substantial capital requirements — Arcellx expects operating expenses to increase substantially and will need significant additional funding to advance its pipeline and platforms [sec_mda · as of 2025-11-05].
- Clinical and regulatory risk — Product development is highly risky; any candidate may fail to demonstrate adequate efficacy or safety, gain approval, or become commercially viable [sec_mda · as of 2026-02-26].
- History of net losses — The company has incurred losses every period since inception, with a net loss of $228.9 million in 2025 and accumulated deficit of $725.8 million [sec_mda · as of 2026-02-26].
What to watch
- Clinical data updates from the Phase 1 study of anito-cel (NCT05457010) in relapsed/refractory multiple myeloma [catalyst].
- Progress in advancing anito-cel into earlier lines of therapy in collaboration with Kite [sec_mda · as of 2025-11-05].
- Regulatory milestones and potential approval filings for anito-cel [sec_mda · as of 2026-02-26].
- Updates on the development of the ARC-SparX platform and other pipeline candidates [sec_mda · as of 2026-02-26].
Sources: Catalysts · SEC MD&A · Generated August 14, 2026 · How we verify sources →
Run Arcellx, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Arcellx, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
22.5 months
D/E 0.50
Lead: Phase 1
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
240
Total value held
$6.47B
| Holder | Shares | Value |
|---|---|---|
| gilead sciences, inc. | 6,720,803 | $771.7M |
| paradigm biocapital advisors lp | 5,774,016 | $663.0M |
| vanguard capital management llc | 4,850,436 | $556.9M |
| blackrock, inc. | 3,945,238 | $453.0M |
| nea management company, llc | 3,045,262 | $349.7M |
| pentwater capital management lp | 2,870,000 | $329.5M |
| vanguard portfolio management llc | 2,424,818 | $278.4M |
| sr one capital management, lp | 2,346,630 | $269.4M |
| fil ltd | 2,339,192 | $268.6M |
| hbk investments l p | 2,278,517 | $261.6M |
Showing top 10 of 240 institutional holders of Arcellx, Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 4.2%
- Days to cover
- 1.6
- Shares short
- 1,800,274
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ACLX short interestGovernance
Frequently asked questions
What is the AI investment thesis for Arcellx, Inc.?
Arcellx, Inc. is a clinical-stage biotechnology company developing novel cell therapies for cancer, primarily its lead candidate anito-cel (a BCMA-targeted CAR-T therapy) in collaboration with Kite, a Gilead company. The company has incurred significant losses since inception and expects to require substantial additional funding to advance its pipeline and platforms.
What is Arcellx, Inc.'s lead drug candidate?
Arcellx, Inc.'s most advanced tracked candidate is anito-cel (Phase 1) for Muscular Diseases.
Who is the CEO of Arcellx, Inc.?
Mr. Rami Elghandour is the chief executive officer of Arcellx, Inc. (ACLX).
Where is Arcellx, Inc. headquartered?
Arcellx, Inc. (ACLX) is headquartered in Redwood City, CA, United States.
What therapeutic areas does Arcellx, Inc. focus on?
Arcellx, Inc. develops therapies across Oncology, Neurology, Immunology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.